News articles about Arcturus Therapeutics (NASDAQ:ARCT) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arcturus Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.3130152628797 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Watch the Active stock of Yesterday— Arcturus Therapeutics Ltd. (ARCT) (stockmarketstop.com)
- Don’t Miss This Stock: Arcturus Therapeutics Ltd. (ARCT),Issuer Direct Corporation (ISDR) (bitcoinpriceupdate.review)
- Blustering Stocks: Camtek Ltd. (NASDAQ:CAMT), Attis Industries, Inc. (NASDAQ:ATIS), Arcturus Therapeutics Ltd … (journalfinance.net)
- Digging Into the Earnings & Quant Data For These Shares: Arcturus Therapeutics Ltd. (NasdaqGM:ARCT), Lumber … (zeelandpress.com)
Several research firms have recently commented on ARCT. Zacks Investment Research upgraded shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 12th. WBB Securities upgraded shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, June 11th. LADENBURG THALM/SH SH upgraded shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating in a report on Thursday, May 31st. Finally, ValuEngine upgraded shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Arcturus Therapeutics presently has a consensus rating of “Buy” and an average target price of $4.06.
Shares of NASDAQ ARCT traded down $0.09 during trading hours on Thursday, hitting $7.91. 32,211 shares of the stock were exchanged, compared to its average volume of 14,126. The firm has a market cap of $87.03 million, a PE ratio of -2.24 and a beta of 1.44. Arcturus Therapeutics has a 12 month low of $4.78 and a 12 month high of $15.19.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Read More: Investing in Dividend Stocks
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.